Currently submitted to: JMIR Research Protocols
Date Submitted: Mar 19, 2024
Open Peer Review Period: Mar 20, 2024 - May 15, 2024
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preventing Premature PrEP Discontinuation and Sexually Transmitted Infections among Men Who Have Sex with Men: Protocol for Prospective Cohort Study (Project PEACH)
ABSTRACT
Background:
There is an ongoing syndemic of human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) in the United States, particularly among men who have sex with men (MSM). We have increasingly effective and diverse measures of prevention, including various types of pre-exposure prophylaxis (PrEP) for HIV prevention and doxycycline post-exposure prophylaxis (doxyPEP) for STI prevention. As options expand, we need to best understand how to use a combination of these strategies and other supports for MSM to best curb the syndemic.
Objective:
We designed a patient-preference trial to understand patient preferences of PrEP and doxyPEP, how preferences may change over time, and methods for preventing premature discontinuation of PrEP.
Methods:
We enrolled HIV-negative MSM in metropolitan Atlanta. Participants could elect to take PrEP (daily or on-demand), doxyPEP, both, or neither, along with app-based support to evaluate for risk factors of discontinuation or behavioral changes that might affect their choice of prevention methods. Participants were able to switch prevention methods at any time. Oral PrEP and doxyPEP users are offered quarterly in-person or at-home HIV, syphilis, gonorrhea, and chlamydia testing along with opportunities for motivational interviewing.
Results:
We enrolled individuals from 11/2021 to 9/2023. Among 240 participants, median age was 30 (interquartile range 25-35), 63% self-identified as non-Hispanic Black, and 69% were insured. Most participants (60%) elected to take daily PrEP plus doxyPEP, with a smaller proportion taking on-demand PrEP plus doxyPEP (14%) or daily PrEP without doxyPEP (14%).
Conclusions:
We designed an ongoing study to evaluate the preferences for PrEP and doxyPEP among MSM in metropolitan Atlanta. Enrollment was completed in 22 months and included a diverse cohort of MSM that will be followed longitudinally to evaluate prevention preferences over time. At baseline, most participants preferred to take a combination of daily PrEP and doxyPEP for HIV and STI prevention. Clinical Trial: Clinicaltrials.gov ID: NCT05072093
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.